The historical rank and industry rank for KORU Medical Systems's ROE % or its related term are showing as below:
KRMD'
s ROE % Range Over the Past 10 Years
Min: -53.18 Med: -10.16 Max: 11.69
Current: -13.68
During the past 13 years, KORU Medical Systems's highest ROE % was 11.69%. The lowest was -53.18%. And the median was -10.16%.
KRMD's ROE % is ranked worse than 69.13% of 797
companies
in the Medical Devices & Instruments industry
Industry Median: 2.4
vs KRMD: -13.68
KORU Medical Systems (NAS:KRMD) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, KORU Medical Systems's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
KORU Medical Systems ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, KORU Medical Systems's ROE % distribution charts can be found below:
* The bar in red indicates where KORU Medical Systems's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
KORU Medical Systems (KRMD) has a ROE % of -19.01% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on KORU Medical Systems and its competitors. According to the industry distribution chart, KORU Medical Systems ranks #551 out of 797 companies in the Medical Devices & Instruments industry, placing it in the top 69.1%.
Is KORU Medical Systems' ROE % too high?
KORU Medical Systems' current ROE % is -19.01%. Based on the distribution chart, KORU Medical Systems ranks #551 out of 797 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, KORU Medical Systems has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does KORU Medical Systems' ROE % compare to EMBC and PDEX?
According to the Medical Devices & Instruments industry distribution chart, KORU Medical Systems ranks #551 out of 797 companies for ROE %. This places KORU Medical Systems in the lower half of its industry. The industry median ROE % is 2.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.40, based on 797 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on KORU Medical Systems and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. KORU Medical Systems's current ROE % is -19.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KORU Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, KORU Medical Systems (KRMD) is currently considered Fairly Valued. The stock's GF Value™ is $4.08, compared to a current price of $4.44 — trading 8.8% above its estimated fair value. The current ROE % is -19.01%. KORU Medical Systems' overall GF Score™ is 76/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For KORU Medical Systems (KRMD), the current ROE % is -19.01% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is KORU Medical Systems (KRMD) Overvalued in 2026?
Based on GuruFocus' analysis, KORU Medical Systems stock appears to be overvalued.
The current stock price of $4.44 is trading 8.8% above its estimated GF Value™ of $4.08.
GuruFocus considers KORU Medical Systems to be Fairly Valued.
Key valuation signals for KRMD:
ROE %: -19.01%
GF Value™: $4.08 vs. price of $4.44 (8.8% above fair value)
No single metric tells the full story. See the KRMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.
76GF Score
Get the complete analysis for KRMD
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KRMD has been successfully added to your 
